DESIGN OF KYSA-6, A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF KYV-101, A NOVEL FULLY HUMAN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN REFRACTORY GENERALIZED MYASTHENIA GRAVIS

被引：0
|
作者：
Haghikia, Aiden
Borie, Dominic
Chung, James
Gold, Ralf
机构：
来源：
MUSCLE & NERVE | 2024年 / 70卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
183
引用
收藏
页码：542 / 542
页数：1
相关论文
共 50 条
  • [41] A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
    Wan-Hong Zhao
    Jie Liu
    Bai-Yan Wang
    Yin-Xia Chen
    Xing-Mei Cao
    Yun Yang
    Yi-Lin Zhang
    Fang-Xia Wang
    Peng-Yu Zhang
    Bo Lei
    Liu-Fang Gu
    Jian-Li Wang
    Nan Yang
    Ru Zhang
    Hui Zhang
    Ying Shen
    Ju Bai
    Yan Xu
    Xu-Geng Wang
    Rui-Li Zhang
    Li-Li Wei
    Zong-Fang Li
    Zhen-Zhen Li
    Yan Geng
    Qian He
    Qiu-Chuan Zhuang
    Xiao-Hu Fan
    Ai-Li He
    Wang-Gang Zhang
    Journal of Hematology & Oncology, 11
  • [42] Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    GWierda, William
    Bishop, Michael R.
    Oluwole, Olalekan
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [43] A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma
    Asghar, Kanwal
    Zafar, Maryam
    Holland, Eva
    Abduljabbar, Ali Bin
    Albagoush, Sara A.
    Asghar, Noureen
    Sood, Akshat
    Dufani, Jalal M.
    Thirumalaredy, Joseph
    Devrieze, Bradley
    Tauseef, Abubakar
    Husnain, Muhammad
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL
    Niu, Panpan
    Hu, Qianli
    Mo, Jialu
    Meng, Guangrong
    Jia, Xiangyin
    Cheng, Wei
    Wei, Qiaoe
    Dai, Zhenyu
    Wu, Xuefeng
    Hu, Guang
    Tan, Taochao
    Zhou, Jianfeng
    Yang, Yongkun
    Hu, Gang
    CANCER RESEARCH, 2022, 82 (12)
  • [45] UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
    Benjamin, Reuben
    Jain, Nitin
    Maus, Marcela V.
    Boissel, Nicolas
    Graham, Charlotte
    Jozwik, Agnieszka
    Yallop, Deborah
    Konopleva, Marina
    Frigault, Matthew J.
    Teshima, Takanori
    Kato, Koji
    Boucaud, Floriane
    Balandraud, Svetlana
    Gianella-Borradori, Athos
    Binlich, Florence
    Marchiq, Ibtissam
    Dupouy, Sandra
    Almena-Carrasco, Maria
    Pannaux, Matthieu
    Fouliard, Sylvain
    Brissot, Eolia
    Mohty, Mohamad
    LANCET HAEMATOLOGY, 2022, 9 (11): : E833 - E843
  • [46] Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study (vol 22, pg 578, 2023)
    Granit, V
    Benatar, M.
    Kurtoglu, M.
    LANCET NEUROLOGY, 2023, 22 (09): : E10 - E10
  • [47] Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system
    Zhang, Huan
    Liu, Man
    Li, Qing
    Lyu, Cuicui
    Jiang, Yan-Yu
    Meng, Juan-Xia
    Li, Jing-Yi
    Deng, Qi
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 353 - 361
  • [48] Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy
    Gong, Wen-Jie
    Qiu, Yan
    Li, Ming-Hao
    Chen, Li-Yun
    Li, Yan-Yan
    Yu, Jing-Qiu
    Kang, Li-Qing
    Sun, Ai-Ning
    Wu, De-Pei
    Yu, Lei
    Xue, Sheng-Li
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [49] Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
    Chong, Elise A.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Winchell, Nicole
    Napier, Ellen
    Mato, Anthony R.
    Melenhorst, J. Joseph
    Ruella, Marco
    Lacey, Simon F.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2018, 132
  • [50] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Topp, M. S.
    Shah, B. D.
    Ghobadi, A.
    Oluwole, O. O.
    Logan, A. C.
    Boissel, N.
    Cassaday, R. D.
    Forcade, E.
    Bishop, M. R.
    Tzachanis, D.
    O'Dwyer, K. M.
    Arellano, M. L.
    Lin, Y.
    Baer, M. R.
    Schiller, G. J.
    Dong, J.
    Shen, T.
    Milletti, F.
    Masouleh, Kharabi B.
    Houot, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 16
12345